1 Olanow CW.Selegiling:current perspectives on issues related to neuroprotection and mortality.Neuro log y,1996;47(Suppl3):S210
2 Tatton WG,Ju WYL,Holland DP,et al.Depreny lreduces PC12 cell apoptosis by inducing new protein synthesis.J Neurochem,1994;63:1572
3 Tatton WG,Ansari K,Ju W,et al.Selegiline induces“trophic-like ”rescue of dying neurons without MAO inhibition.Adv Exp Md Biol,1995;363:15
4 Tatton WG,Greenwood C E.Rescue of dying neurons:a new action for deprenyl in MPTP parkinsonism.J Neurosci Res,1991;30:666
5 My tilineou C,Radcliffe P,Leonardi EK,et al.L-deprenyl protects mesencephalic dopamineneurons from glutamate receptor-mediated to xicityincitro.J Neur ochem,1997;68:33
6 Sliver DE,Ruggieri S.Initiating therapy for Parkinson's disease.neurology,1998;50(Supple6):S18
7 Parkinson Study Group.Inpact of deprenyl and to copherolt reatment on Parkinson's disease in DATATOP patients requiring levodopa.Ann Neuro l,1996;39:37
8 Lees AJ.Comparison of therapeuticeffects andmortalitydata of levodopa and levodopa combined with selegiline in patients with early,mild Parkinson's disease.BM J,1995;311:1602
9 Olanow CW,Fahn S,Langston JW,et al.Selegiline and mortality in Parkinson's disease.Ann Neurol,1996;40:841
10 Parkinson study group.Effects of tocopherol and deprenylon the progression of disability in early Parkinson's disease.N Engl J Med,1993;328:176
11 Olanow CW,Hauser RA,Gauger L,et al.The effect of deprenyl and levodopa on the progression of Parkinson's disease.Ann Neurol,1995;38:771
12 Olanow CW.A rationale for using dopamine agonists as primary symptomatic the rapy in Parkinson's disease.In:O lanow CW,Obeso JA,eds.Dopamine agonists in early Parkinson 's disease.Kent,UK:Wells Medical,1997:37
13 Ogawa N,Tanaka K,Asanuma M,et al.Br om-ocritine protects mice against6-hydro xydopamine and scavenges hydroxyl free radicals invitro.Brain Res,1994;657:207
14 Olanow CW,Jenner P,Youdim M.Neurodegen-eration and neuropro tection in Parkinson 's dis-ease.London:Academic Press,1996
15 Bra vi D,Mouradian M M,Roberts JW,et al.Wearing-offfluctuations in Parkinson's disease:contribution of postsynaptic me chanisms.Ann Neur ol,1994;36:27
16 Verhagen-Metman L,Locate lli ER,Bra vi D,et al.Apomorphine responses in Parkinson's dis-ease and the pathogenesis of motor complications.Neurology,1997;48:369
17 Blo ck G,Liss C,Reines S,et al.Comparison of immediate-release and controlled-release carbidopa/l evodopa in Parl inson's disease:a multicenter5-year study.Eur Neurol,1997;37:23
18 Rinne UK.Cont rolled-releasele vodopa superior to standar dlevodopa in the treatment of early Parkinson's disease.Mov Disord,1990;5(S uppl1):52
19 DupontE,Ander sen A,Bo as J,et al.Sustained -release Madopar HBS compared with standard Madopar in the long-termtreatment of denovoparkinsonian patients.Acta Neuro l Scand,1996;93:14
20 Olanow CW.A radicalhypo thesis for neurodegen-eration.Treds Neur osci,1993;16:439
21 Jenner P,Olanow CW.Oxidative stress and the pathogenesis of Parkinson's disease.Neurology,1996;47(Supp;3):S161
22 FahnS,cohen G.The oxidant stress hypothesis in Parkinson's disease:evidence supporting it Ann Neuro l,1992;32:804
23 Blunt SB,Jenner P,Marsden CD.Suppressive effect of L-dopaon dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin6-hydro xydopamine.Mov Disord,1993;8:129
24 Og aw a N,Asanuma M,Kondo Y,et al.Differ-ential effects o f chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with6-hydrox ydopamine.Meurosci Lett,1994;171:55
25 Jenne r PG,Brin M F.Levodapa neurotoxicity:Expe rimental studies versus clinical relev ance.Neurology,1998;50(Suppl6):S39
26 Kurth M C,Adler CH.COM T inhibition:A new treatment strategy for parkinson's disease.Neu-rology,1998;50(Suppl5):S3
27 Eden RJ,Costall B,Domeney AM,et al.Pre-clinical pharmacolog y o f ropinirole (SK ＆ F101468 -A)a novel dopamine D2 agonist.Phar-macol Bio chem Behav,1991;38:147
28 A Rabey JM.Second gene ration of dopamine agonists:pros and cons.J Neural Transm,1995;45(Suppl):213
29 Olanow CW.A rationale f or dopamine agonists a sprimary therapy for Parkinson's disease.Can J Neuro l Sci,1992;19:108
30 Goe tz CG.Highlights o f the No rt h American and European experiences.Neurology,1998;50(Suppl5):S15
31 Adler CH,Singe r C,Brien CO,et al.Random-ized place controlled study of tolcapone in patients with fluctuation Parkinson's disease treated with levodopa-carbidopa.Arch Neurol,1998;55:1089
32 Goetz CG.Influence of COMT inhibition on levodopa pharmaco logy and the rapy.Neuro log y,1998;50(Suppl5):26
33 Jorg a KM.Pharma cokinetics,pharmacodynamics,and tolerability of tolcapone:Are view of early studiesin voluteers.Neurology,1998;50(Suppl5):31
34 Waters CH,Kurth M,Bailey P,et al.To lcapone in stable parkinson's disease:efficacy and safrty of long-term treatment.Neurology,1998;50(Suppl5):39
35 Baas H,Beiske AG,Ghika J,et al.Catechol-O-methyltr ansferase inhibition with tolcapone reduce s the “wearing-of f”phenomenon and levodopar equire ments in fluctuatiog parkinson patients.Neuro logy,1998;50(Suppl5):46
36 Rajput AH,Martin W,Hilaire's MH,et al.Tolcapone improves motorfunction in parkinsonian patients with the “wearing off ”phenomenon:Adouble-blind,placebo-controlled,multicenter trial.neurology,1998;50(Suppl5):54
37 Hauser RA,Olanow CW.Or obuccaldy skinesia associated with trihexyphenidyl the rapy in apatientswith Parkinson 's disease.Mov Disord,1993;8:512
38 Miller R,Chouinard G.Lo ss of striatal choline rgicneurons a sabasis for tardive and L-dopa-induced dyskinesias,neuroleptic-induced supe rsensitivitypsy chosis and refractory schizophrenia.Biol Psychiatry,1993;34:713
39 Kornhube r J,Weller M,Schoppmeyer K,et al.Amant adine and memantine are NM DA recepto rantagonists with neuropro tective pr oper ties.J Neur al Transm,1994;43(S uppl):91
40 Greenamyre JT,O 'Br ien CF.N-me thy l-D-asparateantagonists in the treatment of Parkin-son's disease.Arch Neurol,1991;48:977
41 Uit ti RJ,Rajput AH,Ahlsko g J R,et al.Amantadine treatment is an independent predicto rof improved survival in Parkinson 's disease.Neurology,1996;46:1551
42 Stoof JC,BooijJ,Drukarch B.Amantadine as N-methy l-D-aspartic acidre ceptorantagonist:new possibilities for ther apeutic applications? Clin Neu-rol Neuro surg,1992;94(Suppl ):4 |
